InVivoMAb Anti-Human IFNB1/IFN-beta Antibody (Iv0199)

Description: InVivoMAb Anti-Human IFNB1/IFN-beta Antibody (Iv0199) [Iv0199] (RA12634) is a human monoclonal antibody detecting Interferon beta in ELISA, Neutralization. Suitable for Human.
Host species: Human
Isotype: IgG1, kappa
Species reactivity: Human
Form: Liquid
Storage buffer: 0.01M PBS, pH 7.4.
Concentration: 1.2 mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: ELISA, Neutralization
Target: Interferon beta, IFN-beta, Fibroblast interferon, IFNB1, IFB, IFNB
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: Please contact with the lab for this information.
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names:
Background: Interferon beta (IFNB1/IFN-beta) is a ~22 kDa protein. Type I interferon cytokine that plays a key role in the innate immune response to infection, developing tumors and other inflammatory stimuli. Signals via binding to high-affinity (IFNAR2) and low-affinity (IFNAR1) heterodimeric receptor, activating the canonical Jak-STAT signaling pathway resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response, such as antiviral proteins, regulators of cell proliferation and differentiation, and immunoregulatory proteins. Signals mostly via binding to a IFNAR1-IFNAR2 heterodimeric receptor, but can also function with IFNAR1 alone and independently of Jak-STAT pathways. Elicits a wide variety of responses, including antiviral and antibacterial activities, and can regulate the development of B-cells, myelopoiesis and lipopolysaccharide (LPS)-inducible production of tumor necrosis factor. Plays a role in neuronal homeostasis by regulating dopamine turnover and protecting dopaminergic neurons: acts by promoting neuronal autophagy and alpha-synuclein clearance, thereby preventing dopaminergic neuron loss.
References:
1. Russell-Harde, D. et al. (1999) Biochemical and biophysical research communications 255, 539-44. PMID: 10049744
2. Piehler, J. et al. (1999) Journal of molecular biology 294, 223-37. PMID: 10556041
3. Derynck, R. et al. (1980) Nature 285, 542-7. PMID: 6157094
4. Shepard, HM. et al. (1981) Nature 294, 563-5. PMID: 6171735
5. Domanski, P. et al. (1995) The Journal of biological chemistry 270, 21606-11. PMID: 7665574
6. Platanias, LC. et al. (1994) The Journal of biological chemistry 269, 17761-4. PMID: 8027027
7. Croze, E. et al. (1996) The Journal of biological chemistry 271, 33165-8. PMID: 8969169
Note: For research use only. Not suitable for clinical or therapeutic use.